Collagen-targeted PET Imaging for Early Interstitial Lung Disease

This study is looking for first-degree relatives (like a parent, child, or sibling) of someone with pulmonary fibrosis (scarring of the lungs) who are over 40 and haven't smoked in the last 6 months. The goal is to see if a special imaging technique using an injection called [68Ga]CBP8 can find early signs of interstitial lung disease (a group of diseases that cause progressive scarring of the lungs). You would receive an injection of [68Ga]CBP8 and another drug called Dotarem, followed by a PET-MRI scan. Researchers want to see how much [68Ga]CBP8 is taken up by your lungs, as this could help predict how the disease might progress. The study plans to enroll 30 participants, but its current status is unclear.

Study design: This interventional study plans to enroll 30 participants. It aims to see if [68Ga]CBP8 can detect collagen deposition in early interstitial lung disease.
What's involved: You would receive an intravenous injection of [68Ga]CBP8 and Dotarem, followed by a PET-MRI scan.
Compensation: Not stated in the trial record.
Follow-up: The degree of uptake of [68Ga]CBP8 will be measured at 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Recruiting

PHASE2Ages 40+InterventionalDiagnostic

Massachusetts General Hospital

~30 participants

Updated 2026-04-20 on ClinicalTrials.gov

What's tested:[68Ga]CBP8Dotarem

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Degree of uptake of [68Ga]CBP8

Measured over 24 months

Conditions

Interstitial Lung Disease

Where it's being run

1 sites across 1 states

Massachusetts1

Who to contact

Sydney B Montesi, MD

[email protected]

617-724-4030

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Age greater than 40 years

Have the ability to give written informed consent

First degree relative of a family member with pulmonary fibrosis

No known history of interstitial lung disease

No tobacco use within the prior 6 months.

Age greater than 40 years

Have the ability to give written informed consent

ILAs or early ILD (defined by presence of reticular markings and / or traction bronchiectasis but absence of a definite UIP pattern)

No tobacco use within the prior 6 months.

Exclusion

Electrical implants such as cardiac pacemaker or perfusion pump

Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing

Historical eGFR of less than 30 mL/min/1.73 m2

Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate)

Claustrophobic reactions

Research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months)

Unable to lie comfortably on a bed inside the MR-PET

BMI \> 33 (limit of the PET-MRI table)

Determined by the investigator(s) to be clinically unsuitable for the study (e.g. based on screening visit and/or during study procedures)

Pneumonia or other acute respiratory illness within 6 weeks of study entry

Parenchymal lung disease except for ILD/ILAs or emphysema

Acute exacerbation of ILD within the prior 6 months

VATS within the prior 6 months

Prior radiation therapy to the thorax

Known allergy to gadolinium.

What this trial measures

Degree of uptake of [68Ga]CBP824 months
The degree of uptake of \[68Ga\]CBP8 in the lungs will be compared between groups and associations with disease severity and progression will be determined.

Trialytics